NPC1L1 and urinary bladder carcinoma: A more recent investigation found that 17,708 post-coronary syndrome patients, either randomized to the ezetimibe group, a cholesterol absorption inhibitor that blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1) on the intestinal villi of the enterocytes, or the matching placebo group, had similar incidences of malignancy and malignancy-related death, including bladder cancer (30).